Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn’s Disease and Ulcerative Colitis—A Prospective Polish Population Study

Background: Primary lack or secondary loss of response to therapy with infliximab is a significant problem. This study aimed to evaluate the response to treatment in patients with Crohn’s disease (CD) and ulcerative colitis (UC) achieving therapeutic and sub-therapeutic trough levels of biosimilar i...

Descripción completa

Detalles Bibliográficos
Autores principales: Pękala, Anna, Filip, Rafał
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619897/
https://www.ncbi.nlm.nih.gov/pubmed/34830598
http://dx.doi.org/10.3390/jcm10225311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619897/
https://www.ncbi.nlm.nih.gov/pubmed/34830598
http://dx.doi.org/10.3390/jcm10225311

Ejemplares similares